FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382752021> ?p ?o ?g. }

• W4382752021 endingPage "699" @default.
• W4382752021 startingPage "687" @default.
• W4382752021 abstract "Abstract ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. We further characterize AEs of acalabrutinib and ibrutinib via post hoc analysis. Overall and exposure-adjusted incidence rate was assessed for common Bruton tyrosine kinase inhibitor–associated AEs and for selected events of clinical interest (ECIs). AE burden scores based on previously published methodology were calculated for AEs overall and selected ECIs. Safety analyses included 529 patients (acalabrutinib, n = 266; ibrutinib, n = 263). Among common AEs, incidences of any-grade diarrhea, arthralgia, urinary tract infection, back pain, muscle spasms, and dyspepsia were higher with ibrutinib, with 1.5- to 4.1-fold higher exposure-adjusted incidence rates. Incidences of headache and cough were higher with acalabrutinib, with 1.6- and 1.2-fold higher exposure-adjusted incidence rate, respectively. Among ECIs, incidences of any-grade atrial fibrillation/flutter, hypertension, and bleeding were higher with ibrutinib, as were exposure-adjusted incidence rates (2.0-, 2.8-, and 1.6-fold, respectively); incidences of cardiac events overall (the Medical Dictionary for Regulatory Activities system organ class) and infections were similar between arms. Rate of discontinuation because of AEs was lower for acalabrutinib (hazard ratio, 0.62; 95% confidence interval, 0.41-0.93). AE burden score was higher for ibrutinib vs acalabrutinib overall and for the ECIs atrial fibrillation/flutter, hypertension, and bleeding. A limitation of this analysis is its open-label study design, which may influence the reporting of more subjective AEs. Overall, event-based analyses and AE burden scores demonstrated higher AE burden overall and specifically for atrial fibrillation, hypertension, and hemorrhage with ibrutinib vs acalabrutinib. This trial was registered at www.clinicaltrials.gov as #NCT02477696." @default.
• W4382752021 created "2023-07-01" @default.
• W4382752021 creator A5006104041 @default.
• W4382752021 creator A5010286156 @default.
• W4382752021 creator A5013974745 @default.
• W4382752021 creator A5014241029 @default.
• W4382752021 creator A5016570475 @default.
• W4382752021 creator A5016818736 @default.
• W4382752021 creator A5019866348 @default.
• W4382752021 creator A5026397606 @default.
• W4382752021 creator A5027492391 @default.
• W4382752021 creator A5045655215 @default.
• W4382752021 creator A5046659441 @default.
• W4382752021 creator A5064164625 @default.
• W4382752021 creator A5069774776 @default.
• W4382752021 creator A5081326206 @default.
• W4382752021 creator A5081357560 @default.
• W4382752021 creator A5083072418 @default.
• W4382752021 creator A5083681267 @default.
• W4382752021 creator A5090615083 @default.
• W4382752021 date "2023-08-24" @default.
• W4382752021 modified "2023-10-17" @default.
• W4382752021 title "Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR" @default.
• W4382752021 cites W2107820445 @default.
• W4382752021 cites W2115086589 @default.
• W4382752021 cites W2142099365 @default.
• W4382752021 cites W2167571044 @default.
• W4382752021 cites W2316021978 @default.
• W4382752021 cites W2473786944 @default.
• W4382752021 cites W2558640761 @default.
• W4382752021 cites W2561449166 @default.
• W4382752021 cites W2613723809 @default.
• W4382752021 cites W2750906538 @default.
• W4382752021 cites W2770172979 @default.
• W4382752021 cites W2787916641 @default.
• W4382752021 cites W2808391935 @default.
• W4382752021 cites W2915082572 @default.
• W4382752021 cites W2922286357 @default.
• W4382752021 cites W2942273225 @default.
• W4382752021 cites W2978550355 @default.
• W4382752021 cites W3094484041 @default.
• W4382752021 cites W3096320898 @default.
• W4382752021 cites W3096800474 @default.
• W4382752021 cites W3108628542 @default.
• W4382752021 cites W3151974300 @default.
• W4382752021 cites W3185756680 @default.
• W4382752021 cites W3186824000 @default.
• W4382752021 cites W3212887667 @default.
• W4382752021 doi "https://doi.org/10.1182/blood.2022018818" @default.
• W4382752021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37390310" @default.
• W4382752021 hasPublicationYear "2023" @default.
• W4382752021 type Work @default.
• W4382752021 citedByCount "3" @default.
• W4382752021 countsByYear W43827520212023 @default.
• W4382752021 crossrefType "journal-article" @default.
• W4382752021 hasAuthorship W4382752021A5006104041 @default.
• W4382752021 hasAuthorship W4382752021A5010286156 @default.
• W4382752021 hasAuthorship W4382752021A5013974745 @default.
• W4382752021 hasAuthorship W4382752021A5014241029 @default.
• W4382752021 hasAuthorship W4382752021A5016570475 @default.
• W4382752021 hasAuthorship W4382752021A5016818736 @default.
• W4382752021 hasAuthorship W4382752021A5019866348 @default.
• W4382752021 hasAuthorship W4382752021A5026397606 @default.
• W4382752021 hasAuthorship W4382752021A5027492391 @default.
• W4382752021 hasAuthorship W4382752021A5045655215 @default.
• W4382752021 hasAuthorship W4382752021A5046659441 @default.
• W4382752021 hasAuthorship W4382752021A5064164625 @default.
• W4382752021 hasAuthorship W4382752021A5069774776 @default.
• W4382752021 hasAuthorship W4382752021A5081326206 @default.
• W4382752021 hasAuthorship W4382752021A5081357560 @default.
• W4382752021 hasAuthorship W4382752021A5083072418 @default.
• W4382752021 hasAuthorship W4382752021A5083681267 @default.
• W4382752021 hasAuthorship W4382752021A5090615083 @default.
• W4382752021 hasBestOaLocation W43827520211 @default.
• W4382752021 hasConcept C120665830 @default.
• W4382752021 hasConcept C121332964 @default.
• W4382752021 hasConcept C126322002 @default.
• W4382752021 hasConcept C143998085 @default.
• W4382752021 hasConcept C197934379 @default.
• W4382752021 hasConcept C207103383 @default.
• W4382752021 hasConcept C2777938653 @default.
• W4382752021 hasConcept C2778461978 @default.
• W4382752021 hasConcept C2778715236 @default.
• W4382752021 hasConcept C2779878957 @default.
• W4382752021 hasConcept C44249647 @default.
• W4382752021 hasConcept C61511704 @default.
• W4382752021 hasConcept C71924100 @default.
• W4382752021 hasConcept C90924648 @default.
• W4382752021 hasConceptScore W4382752021C120665830 @default.
• W4382752021 hasConceptScore W4382752021C121332964 @default.
• W4382752021 hasConceptScore W4382752021C126322002 @default.
• W4382752021 hasConceptScore W4382752021C143998085 @default.
• W4382752021 hasConceptScore W4382752021C197934379 @default.
• W4382752021 hasConceptScore W4382752021C207103383 @default.
• W4382752021 hasConceptScore W4382752021C2777938653 @default.
• W4382752021 hasConceptScore W4382752021C2778461978 @default.
• W4382752021 hasConceptScore W4382752021C2778715236 @default.
• W4382752021 hasConceptScore W4382752021C2779878957 @default.

• next